BioSyntech Appoints Chief Executive Officer

18-Aug-2009 - Canada

BioSyntech, Inc. announced that it has appointed Ms. Jeanne Bertonis, MBA, M.Sc., to the role of Chief Executive Officer. The Company previously announced that Ms. Bertonis was retained by BioSyntech as a consultant to assist the Company with its research and development, regulatory, strategic planning and business development strategies.

Ms Bertonis has been a management consultant for the last three years, providing strategic and business advice primarily to venture capital groups and private biomedical companies, with a focus on biomaterials, cardiovascular and orthopedics industries. She held the positions of Chief Business Officer and Vice President, Corporate Development for Angiotech Pharmaceuticals from 2000-2006, where she oversaw all of its business and corporate development functions, including mergers and acquisitions, strategic collaborations, and marketing. Prior to joining Angiotech, she held senior business development positions at Guidant and Genzyme, working across a broad spectrum of industries including devices, drugs, combination therapies, gene therapy, cell therapy and bioactive biomaterials.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances